SIRPA and neoplasm: Importantly, consistent with our previous study [15], we found that anti-SIRPα treatment upregulated PD-L1 expression in TIMs, which suggested that SIRPα blockade therapy may inhibit the immune evasion of the tumor (Fig. 3I–L).